BACKGROUND: Lymphocyte cytosolic protein 2, also known as Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons (SLP-76), is an essential adaptor molecule in myeloid cells, where it regulates FcepsilonRI-induced mast cell (MC) and FcgammaR- and integrin-induced neutrophil (polymorphonuclear leukocyte [PMN]) functions. SLP-76 contains 3 N-terminal tyrosines at residues 112, 128, and 145 that together are critical for its function. OBJECTIVE: We sought to explore the relative importance of tyrosines 112, 128, and 145 of SLP-76 during MC and PMN activation. METHODS: We examined in vitro MC and PMN functions using cells isolated from knock-in mice harboring phenylalanine substitution mutations at tyrosines 112 and 128 (Y112/128F) or 145 (Y145F). We also examined the effects of these mutations on in vivo MC and PMN activation using models of anaphylaxis, dermal inflammation, and serum-induced arthritis. RESULTS: Mutations at Y112/Y128 and Y145 both interfered with SLP-76 activity; however, Y145F had a greater effect than Y112/128F on most in vitro FcR-induced functions. In vitro functional defects were recapitulated in vivo, where mice expressing Y145F exhibited greater attenuation of MC-dependent passive systemic anaphylaxis and PMN-mediated inflammatory responses. Notably, the Y145F mutation completely protected mice against development of joint-specific inflammation in the MC and PMN-dependent K/B x N model of arthritis. CONCLUSION: Our data indicate that Y145 is the most critical tyrosine supporting SLP-76 function in myeloid cells. Future efforts to dissect how Y145 mediates SLP-76-dependent signaling in MCs and PMNs will increase our understanding of these lineages and provide insights into the treatment of allergy and inflammation.
BACKGROUND:Lymphocyte cytosolic protein 2, also known as Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons (SLP-76), is an essential adaptor molecule in myeloid cells, where it regulates FcepsilonRI-induced mast cell (MC) and FcgammaR- and integrin-induced neutrophil (polymorphonuclear leukocyte [PMN]) functions. SLP-76 contains 3 N-terminal tyrosines at residues 112, 128, and 145 that together are critical for its function. OBJECTIVE: We sought to explore the relative importance of tyrosines 112, 128, and 145 of SLP-76 during MC and PMN activation. METHODS: We examined in vitro MC and PMN functions using cells isolated from knock-in mice harboring phenylalanine substitution mutations at tyrosines 112 and 128 (Y112/128F) or 145 (Y145F). We also examined the effects of these mutations on in vivo MC and PMN activation using models of anaphylaxis, dermal inflammation, and serum-induced arthritis. RESULTS: Mutations at Y112/Y128 and Y145 both interfered with SLP-76 activity; however, Y145F had a greater effect than Y112/128F on most in vitro FcR-induced functions. In vitro functional defects were recapitulated in vivo, where mice expressing Y145F exhibited greater attenuation of MC-dependent passive systemic anaphylaxis and PMN-mediated inflammatory responses. Notably, the Y145F mutation completely protected mice against development of joint-specific inflammation in the MC and PMN-dependent K/B x N model of arthritis. CONCLUSION: Our data indicate that Y145 is the most critical tyrosine supporting SLP-76 function in myeloid cells. Future efforts to dissect how Y145 mediates SLP-76-dependent signaling in MCs and PMNs will increase our understanding of these lineages and provide insights into the treatment of allergy and inflammation.
Authors: A S Korganow; H Ji; S Mangialaio; V Duchatelle; R Pelanda; T Martin; C Degott; H Kikutani; K Rajewsky; J L Pasquali; C Benoist; D Mathis Journal: Immunity Date: 1999-04 Impact factor: 31.745
Authors: J S Song; H Haleem-Smith; R Arudchandran; J Gomez; P M Scott; J F Mill; T H Tan; J Rivera Journal: J Immunol Date: 1999-07-15 Impact factor: 5.422
Authors: Hongxia Z Imtiyaz; Emily P Williams; Michele M Hickey; Shetal A Patel; Amy C Durham; Li-Jun Yuan; Rachel Hammond; Phyllis A Gimotty; Brian Keith; M Celeste Simon Journal: J Clin Invest Date: 2010-07-19 Impact factor: 14.808
Authors: Mark C Siracusa; Steven A Saenz; David A Hill; Brian S Kim; Mark B Headley; Travis A Doering; E John Wherry; Heidi K Jessup; Lori A Siegel; Taku Kambayashi; Emily C Dudek; Masato Kubo; Antonella Cianferoni; Jonathan M Spergel; Steven F Ziegler; Michael R Comeau; David Artis Journal: Nature Date: 2011-08-14 Impact factor: 49.962
Authors: Helena Block; Jan M Herter; Jan Rossaint; Anika Stadtmann; Stefanie Kliche; Clifford A Lowell; Alexander Zarbock Journal: J Exp Med Date: 2012-01-30 Impact factor: 14.307